Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN727 versus ezetimibe in statin-intolerant primary hypercholesterolemia
NL-OMON39721Phase 3Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Planned start Dec 2012; status: withdrawn.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON39721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39721.